Antiinflammatory strategies, not just B cell depletion, are required for optimal therapy for severe proliferative lupus nephritis: comment on the article by Rovin et al.
Kyriakos A
KA
Kirou
Elena
E
Gkrouzman
James M
JM
Chevalier
Surya V
SV
Seshan
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008181:Lupus Nephritis / Q000188:drug therapy*; D008297:Male
D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents